Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars

Reuters

Jul 17, 2025

Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars

Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2552485955"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552485955\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552485955?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552485955","market":"us","top_or_hot":-1,"title":"Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harrow Inc., a prominent <a href=\"https://laohu8.com/S/FNCSF\">North American</a> eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harrow Inc., a prominent <a href=\"https://laohu8.com/S/FNCSF\">North American</a> eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL9dtc3g:1","article_id":"2552485955","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552485955","pubTimestamp":1752750045,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ and OPUVIZ, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HROW":"Harrow Health Inc","BK4557":"大麻股"},"translate_title":"Harrow Inc.拥有三星Bioepis眼科生物仿制药的独家权利，扩大在美国的业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"Harrow Inc. Expands U.S. Presence with Exclusive Rights to Samsung Bioepis' Ophthalmic Biosimilars\n    \n\n        Harrow Inc., a prominent North American eyecare pharmaceutical company, has announced a strategic expansion through a definitive agreement with Samsung Bioepis Co. Ltd. This agreement grants Harrow exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ® and OPUVIZ™, both FDA-approved biosimilars referencing well-established anti-VEGF therapies Lucentis and Eylea, respectively. Harrow aims to leverage its established commercial infrastructure to enhance market accessibility and affordability of these treatments for retinal diseases, a market valued at $9 billion in the U.S. By 2025, Harrow will assume full commercial responsibility for these products, potentially reducing the financial burden on Medicare and commercial plans while expanding patient access.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717236374) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}